The value of circulating methylated septin 9 in the diagnosis and prognostic assessment of gastric cancer.

ABSTRACT:

Background

Gastric cancer (GC) is a lethal malignancy usually diagnosed at advanced stages due to limited detection methods. Invasive examinations, such as electronic gastroscopy and pathological biopsy, have limitations for large-scale screening, while existing blood biomarkers (CEA, CA19-9, CA72-4) suffer from variable sensitivity and specificity. Methylated septin 9 (mSEPT9), a promising epigenetic biomarker in other cancers, remains understudied in GC.

Materials and methods

This retrospective study included 185 GC patients admitted to Shandong Cancer Hospital and Institute from January 2020 to December 2024. Clinical data were collected, and the levels of mSEPT9, conventional biomarkers (CEA, CA199, CA724), serum gastric function indicators (pepsinogen I [PG I], pepsinog

SUBMITTER: Ni J 

PROVIDER: S-EPMC12511500 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature